Skip to main content

Lurbinectedin Dosage

Medically reviewed by Last updated on Aug 15, 2022.

Applies to the following strengths: 4 mg

Usual Adult Dose for Small Cell Lung Cancer

3.2 mg/m2 IV over 60 minutes every 21 days until disease progression or unacceptable toxicity


  • Initiate this drug only if absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000/mm3.
  • Consider administering pre-infusion medications for antiemetic prophylaxis: Corticosteroids (e.g., dexamethasone 8 mg IV or equivalent) and serotonin antagonists (e.g., ondansetron 8 mg IV or equivalent).

Use: For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy

Renal Dose Adjustments

Mild to moderate renal impairment: No adjustment recommended.
Severe renal impairment: Data not available

Liver Dose Adjustments

Mild hepatic impairment (total bilirubin ULN or less and AST greater than ULN, or total bilirubin 1 to 1.5 x ULN and any AST): No adjustment recommended.
Moderate to severe hepatic impairment (total bilirubin greater than 1.5 x ULN and any AST): Data not available

Dose Adjustments


  • First dose reduction: 2.6 mg/m2 IV over 60 minutes every 21 days
  • Second dose reduction: 2 mg/m2 IV over 60 minutes every 21 days

NEUTROPENIA (patients with isolated Grade 4 neutropenia [neutrophil count less than 500 cells/mm3] may receive G-CSF prophylaxis rather than undergo dose reduction):
  • Grade 4 or any Grade febrile neutropenia: Withhold therapy until resolved to Grade 1 or less; resume therapy at a reduced dose.
  • Grade 3 with bleeding or Grade 4: Withhold therapy until platelet count is 100,000/mm3 or greater; resume therapy at a reduced dose.
  • Grade 2: Withhold therapy until Grade 1 or less; resume therapy at same dose.
  • Grade 3 or greater: Withhold therapy until Grade 1 or greater; resume at reduced dose.



  • None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

  • Advise patients to avoid grapefruit products during therapy with this drug.

Storage requirements:
  • Store this drug refrigerated at 2C to 8C (36F to 46F).
  • This drug is a hazardous drug. Follow applicable special handling and disposal procedures.

  • Hepatotoxicity

Patient advice:
  • Read the approved patient labeling (Patient Information) before you receive this drug the first time and each subsequent dose.
  • Do not become pregnant or breastfeed a child while taking this drug.
  • Inform your healthcare providers of all concomitant medications, herbal. and
dietary supplements.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.